Khan A Zaman, Parry J Michael, Crowley William F, McAllen K, Davis Alan T, Bonnell Bruce W, Hoogeboom James E
Grand Rapids/Michigan State University General Surgery Residency, Grand Rapids Medical Education and Research Center for the Health Professions, 221 Michigan St. NE, Suite 200A, Grand Rapids, MI 49502, USA.
Am J Surg. 2005 Mar;189(3):331-4. doi: 10.1016/j.amjsurg.2004.11.021.
The aim of this study was to determine the dose of recombinant factor VIIa (rFVIIa) that has been used in our institution to successfully control hemorrhage in trauma and postoperative patients.
This was an 8-month retrospective cohort study of 13 patients with acute hemorrhage and no known history of coagulopathic disorders.
Administration of factor VIIa resulted in the cessation of life-threatening hemorrhage at dosages approximately one half those recommended for the management of hemophilia. After administration, there was a significant decrease in the total blood-product transfusion requirement (P <0.05).
The use of factor VIIa in patients with life-threatening hemorrhage is a safe and effective therapeutic modality when used as an adjunct to standard interventions for control of severe hemorrhage. Lower-dose regimens were as successful as higher-dose regimens previously reported. The results of this respective study of 13 patients suggests that recombinant factor VIIa therapy for control of life-threatening hemorrhage as an adjunct to standard interventions can be successful at doses <90 mg/kg.
本研究的目的是确定我院用于成功控制创伤及术后患者出血的重组凝血因子VIIa（rFVIIa）剂量。
这是一项针对13例急性出血且无已知凝血障碍病史患者的为期8个月的回顾性队列研究。
给予凝血因子VIIa后，在大约为血友病治疗推荐剂量一半的情况下，危及生命的出血得以停止。给药后，全血制品输注需求显著降低（P<0.05）。
对于有危及生命出血的患者，当作为控制严重出血的标准干预措施的辅助手段使用时，凝血因子VIIa的应用是一种安全有效的治疗方式。较低剂量方案与先前报道的较高剂量方案同样成功。这项针对13例患者的相应研究结果表明，作为标准干预措施的辅助手段，以<90mg/kg的剂量使用重组凝血因子VIIa治疗危及生命的出血可能会取得成功。
Zotero 插件